IP and R&D Spark Newsletter

This month’s edition explores how innovation is increasingly being shaped by trust, validation, and readiness for real-world adoption. Across industries, stronger data, faster patent processes, credible evidence, and scalable infrastructure are becoming essential to transforming promising ideas into commercially meaningful solutions.

Some highlights from this edition include:

• Industry developments: WIPO’s integration of verified patent-pool data into SEP searches, the EPO’s focus on evidence-backed FRAND valuation, the UK IPO’s transition toward digital-first patent filing, and Korea’s accelerated examination framework for advanced technologies.
• Legal developments: Key rulings involving Samsung’s cellular/Wi-Fi roaming technology dispute, Google’s trademark-keyword advertising case in India, InterDigital’s pan-European injunction against Disney, and Philip Morris’s successful defence in a nicotine-pouch patent dispute.
• Techno Spotlight featuring advancements across:
  • Chemicals & Materials: Research into gold’s resistance to tarnishing, visible-to-UV light conversion, sustainable desalination without toxic brine, and new catalyst-design principles for cleaner energy technologies.
  • Life Sciences: Standardized validation frameworks for cuffless blood-pressure monitoring, wearable ultrasound for continuous fetal monitoring, healthcare-specific foundation AI models, and targeted protein degradation for next-generation therapeutics.
  • Hi-Tech: Enterprise agentic-AI infrastructure, AI-enabled hybrid-work ecosystems, edge-to-cloud AI software platforms, and sub-1-nanometre semiconductor architectures based on three-dimensional transistor integration.
  • Consumer Goods: Conversational AI-powered beauty experiences, strategic expansion in health and wellness nutrition, collaborative probiotic discovery, and sustainable algae-derived DHA for prenatal health.
  • Chemical Safety & Regulatory Affairs: Greener pharmaceutical manufacturing, wider adoption of non-animal safety-testing methods, emerging chemical-safety priorities, regulatory acceptance of AI-based toxicology tools, faster medical-device licensing, flexible clinical-trial models, and evolving antiviral and metabolic drug strategies.
  • Standard Essential Patents: improved access to verified patent-pool records, stronger evidentiary expectations in FRAND-rate determination, and the growing influence of cross-border injunctions and patent-quality analysis on licensing negotiations.

Together, these developments demonstrate that innovation increasingly depends not only on developing new technologies, but also on building the credible data, defensible IP positions, regulatory pathways, and commercial frameworks needed to support their adoption.